Solid Biosciences begins phase 3 trial for Duchenne therapy SGT-003

May 7, 2026 8:00 AM

Solid Biosciences Inc. (NASDAQ: SLDB) dosed the first participant in its Phase 3 IMPACT DUCHENNE clinical trial evaluating SGT-003 for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found